Show simple item record

dc.contributor.authorLee, Sharon Wei Ling
dc.contributor.authorAdriani, Giulia
dc.contributor.authorCeccarello, Erica
dc.contributor.authorPavesi, Andrea
dc.contributor.authorTan, Anthony Tanoto
dc.contributor.authorBertoletti, Antonio
dc.contributor.authorKamm, Roger Dale
dc.contributor.authorWong, Siew Cheng
dc.date.accessioned2018-05-11T19:35:23Z
dc.date.available2018-05-11T19:35:23Z
dc.date.issued2018-03
dc.date.submitted2017-09
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/1721.1/115345
dc.description.abstractIn the hepatitis B virus (HBV)-related hepatocellular carcinoma tumor microenvironment (TME), monocytes reportedly impede natural T cell functions via PD-L1/PD-1 signaling. However, it remains unclear if T cell receptor-redirected T cells (TCR T cells) are similarly inhibited. Hence, we developed a 3D intrahepatic TME microfluidic model to investigate the immunosuppressive potential of monocytes toward HBV-specific TCR T cells and the role of PD-L1/PD-1 signaling. Interestingly, in our 3D static microfluidic model, we observed that monocytes suppressed only retrovirally transduced (Tdx) TCR T cell cytotoxicity toward cancer cells via PD-L1/PD-1, while mRNA electroporated (EP) TCR T cell cytotoxicity was not affected by the presence of monocytes. Importantly, when co-cultured in 2D, both Tdx and EP TCR T cell cytotoxicity toward cancer cells were not suppressed by monocytes, suggesting our 3D model as a superior tool compared to standard 2D assays for predicting TCR T cell efficacy in a preclinical setting, which can thus be used to improve current immunotherapy strategies.en_US
dc.description.sponsorshipSingapore. Prime Minister’s Office. National Resource Foundationen_US
dc.description.sponsorshipSingapore-MIT Alliance for Research and Technology (SMART)en_US
dc.description.sponsorshipSingapore. Biomedical Research Councilen_US
dc.description.sponsorshipSingapore. Agency for Science, Technology and Researchen_US
dc.publisherFrontiers Research Foundationen_US
dc.relation.isversionofhttp://dx.doi.org/10.3389/fimmu.2018.00416en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceFrontiersen_US
dc.titleCharacterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Modelen_US
dc.typeArticleen_US
dc.identifier.citationLee, Sharon Wei Ling, et al. “Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.” Frontiers in Immunology, vol. 9, Mar. 2018. © 2018 Lee, Adriani, Ceccarello, Pavesi, Tan, Bertoletti, Kamm and Wong.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Mechanical Engineeringen_US
dc.contributor.departmentSingapore-MIT Alliance in Research and Technology (SMART)en_US
dc.contributor.mitauthorKamm, Roger Dale
dc.contributor.mitauthorLee, Sharon Wei Ling
dc.relation.journalFrontiers in Immunologyen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2018-05-04T13:47:17Z
dspace.orderedauthorsLee, Sharon Wei Ling; Adriani, Giulia; Ceccarello, Erica; Pavesi, Andrea; Tan, Anthony Tanoto; Bertoletti, Antonio; Kamm, Roger Dale; Wong, Siew Chengen_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-7232-304X
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record